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Background: Malaria parasites and their products can activate a specific immune response by stimulating cytokine
production in the host’s immune cells. Transcription nuclear factor kappa B (NF-κB) is an important regulator for the
control of many pro-inflammatory genes, such as interleukin-1 (IL-1) and tumor necrosis factor (TNF). The activation
and expression of NF-κB p65 in peripheral blood mononuclear cells (PBMCs) of malaria patients were investigated
and correlated with the levels of IL-10 and TNF to study the nature of NF-κB p65 and its linkage to inflammatory
cytokines.
Methods: The sample group comprised 33 patients admitted with malaria caused by Plasmodium vivax (n = 11),
uncomplicated Plasmodium falciparum (n = 11), and complicated Plasmodium falciparum (n = 11). Peripheral blood
was collected at admission and on day 7 for PBMC isolation. Healthy subjects were used as a control group. The
expressions of NF-κB p65 in the PBMCs from malaria patients and the plasma levels of IL-10 and TNF were
measured by using enzyme-linked immunosorbent assay (ELISA). The immunofluorescence technique was used to
determine NF-κB nuclear translocation.
Results: At admission, patients with P. vivax and uncomplicated P. falciparum had significantly elevated phospho-
NF-κB p65 levels in the PBMCs compared with those of healthy controls. However, patients with complicated P.
falciparum malaria had decreased levels of phospho-NF-κB p65. On day 7 post-treatment, significantly increased
phospho-NF-κB p65 was found in the PBMCs of patients with complicated P. falciparum, compared with healthy
controls. The plasma level of IL-10 was elevated in day 0 in patients with complicated P. falciparum malaria and was
found to be negatively correlated with phospho-NF-κB p65 level (rs=−0.630, p= 0.038). However, there was no
correlation between phospho-NF-κB p65 expression and TNF level in patients with complicated P. falciparum
malaria.
Conclusions: This is the first report demonstrating alterations in NF-κB p65 activity in the PBMCs of malaria
patients. The altered lower features of NF-κB p65 in the PBMCs of patients with complicated P. falciparum at
admission could be due to a suppressive effect of high IL-10 associated with complicated P. falciparum malaria.
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Nuclear factor kappa B (NF-κB) plays a crucial role in
immune and inflammatory responses, through the regu-
lation of various genes involved in pro-inflammatory
cytokines, adhesion molecules, chemokines, inducible
enzymes, and apoptosis [1]. Mammals express five NF-
κB protein members: NF-κB-1 (p50), NF-κB-2 (p52), Rel
A (p65), Rel B, and c-Rel [2]. These proteins have a
structurally conserved amino-terminal (300 amino-acid)
region, containing dimerization, nuclear localization and
DNA binding domains. In unstimulated cells, NF-κB is
bound to its inhibitor, the inhibitor kappa B (IκB) pro-
tein, and it appears in the cytoplasm as an inactive form.
Following stimulation, IκB is first phosphorylated by IκB
kinase (IKK) and then rapidly degraded by the proteo-
some. Subsequently, activated NF-κB translocates into
the nucleus, where it binds to the DNA regulatory site
to regulate specific gene expressions [2,3].
The process of malaria pathogenesis is very complex
and still poorly understood. Several studies have indi-
cated that the expression of adhesion molecules on vas-
cular endothelial cells and the production of pro-
inflammatory cytokines are closely linked to the activa-
tion of NF-κB protein transcription. It is already known
that circulating mononuclear cells are involved in the
immune responses and production of pro-inflammatory
cytokines. Accumulated evidence has demonstrated that
excessive production of pro-inflammatory mediators
leads to systemic and organ-related pathological condi-
tions. Previous studies have reported that levels of en-
dogenous pyrogens such as interleukin-6 (IL-6), IL-1β
and IL-8 were elevated in P. vivax and P. falciparum
malaria infections [4-7]. The increasing serum TNF
levels were reported to be associated with increased
mortality in Malawian children with severe malaria [8].
Plasma TNF levels were also found to be higher in Gam-
bian children [9]. A recent study of experimental P. fal-
ciparum infection in malaria-naïve individuals has
shown a coordinated increase in the level of pro-
inflammatory cytokines, including IFN-γ, IL-12 and IL-8
in the serum [10]. Previous in vitro studies have demon-
strated that haemozoin (HZ) [11] and glycosylphosphati-
dylinositol (GPI) [12,13] can stimulate monocytes and
macrophages to synthesize pro-inflammatory cytokines
via NF-κB pathways [12], leading to rapid phosphoryl-
ation of IκB, with subsequent nuclear translocation of
NF-κB [13]. Using a microarray methodology, it has
been reported that the transcripts of Toll-like receptor
signaling through NF-κB pathways was significantly up-
regulated in the peripheral blood mononuclear cells
(PBMCs) of both experimentally and naturally acquired
malaria infections [14]. Aside from the process of
cytoadhesion and sequestration, the pathogenesis of mal-
aria is associated with increased production of pro-inflammatory cytokines. Circulating mononuclear cells
are known to be induced in the immune response, and
are potent biological sensors of infection. No study has
reported the expression of NF-κB in PBMCs from mal-
aria patients and its association with circulating cyto-
kines such as IL-10 and TNF. To elucidate this process,
NF-κB p65 activity in the PBMCs of malaria patients
was determined and correlated with the plasma levels of
IL-10 and TNF as well as with pertinent clinical data.Methods
Malaria patients and healthy controls
Thirty-three malaria patients admitted to the Hospital
for Tropical Diseases, Faculty of Tropical Medicine,
Mahidol University, Thailand, were included in this
study. The patients were divided into three groups: (1)
Plasmodium vivax malaria (n = 11), classified based on a
positive blood smear with P. vivax by microscopic exam-
ination, (2) uncomplicated Plasmodium falciparum mal-
aria (n = 11), classified based on a positive blood smear
with P. falciparum, and no evidence of severe or compli-
cated malaria, and (3) complicated Plasmodium falcip-
arum malaria (n = 11), defined by the WHO criteria [15].
Complicated malaria was defined as patients exhibiting
one or more of the following manifestations: hyperpara-
sitaemia (> 250,000 parasite/μl), hypoglycaemia (glucose
< 22 nmol/l), severe anaemia (haematocrit< 20% or
haemoglobin< 7.0 g/dl), or increased serum level of cre-
atinine of more than 3.0 mg/dl. Cerebral malaria was
defined as unrousable coma with positive asexual forms
of P. falciparum in blood smears, with other causes of
coma excluded. Eleven healthy volunteers living in Bang-
kok, a non-endemic malaria area, were recruited as the
control group. This group had no history of malaria in-
fection. Written informed consent was obtained from all
patients or their legal representatives before enrollment
in the study. The study protocol was approved by the
Ethics Committee, Faculty of Tropical Medicine, Mahi-
dol University (MUTM 2010-053-01).Blood collection
Five milliliters (ml) of peripheral blood was collected in
heparinized tubes from the malaria patients on day 0
(pre-treatment) and day 7 (post-treatment) for PBMC
isolation. In addition, 20 ml of whole blood was obtained
from the healthy controls for PBMC isolation, which
were employed as unstimulated cells, to investigate the
ability of malaria-patient sera to induce NF-κB activa-
tion. To prepare the sera from malaria patients, clotted
blood was centrifuged at 1,700 g for 10 min. The super-
natant representing the serum was harvested and stored
in an aliquoted state at −80°C. The serum was heat-
inactivated at 56°C for 30 min before use.
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PBMCs were isolated from freshly heparinized blood by
gradient centrifugation, using Isoprep® separation
medium (Robbins Scientific, CA, USA), according to the
manufacturer’s instructions. The heparinized blood sam-
ples were centrifuged at 1,700 g for 5 min and plasma
was removed and stored at −80°C until use for cytokine
measurements. The remaining blood samples were
diluted with an equal volume of phosphate-buffered sa-
line (PBS) (pH 7.4), layered carefully into a conical tube
containing Isoprep® solution, then centrifuged at
1,200 g for 25 min. After centrifugation, the PBMCs
were removed and washed three times with PBS. The
cells were stained with trypan blue and counted with a
haemocytometer to determine the number of viable
PBMCs.
Total protein extraction
PBMCs were suspended in ice-cold lysis buffer (Cell Sig-
naling, MA, USA) (20 mM Tris–HCl, 150 mM NaCl,
1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM so-
dium pyrophosphate, 1 mM β-glycerophosphate, 1 mM
Na3VO4, 1 μg/ml leupeptin) and a protease inhibitor
cocktail (Sigma-Aldrich, MO, USA) for 5 min. The
lysates were briefly sonicated on ice, centrifuged at
14,000 g for 10 min at 4°C, and the supernatants were
harvested. Protein concentrations in each sample were
determined by Bradford assay (Pierce Biotechnology, IL,
USA), using bovine serum albumin (BSA) as the
standard.Measurement of total- and phospho-NF-κB p65
The expression of NF-κB p65 in the PBMCs was
assessed by sandwich ELISA kit (Cell Signaling, MA,
USA) according to the manufacturer's protocol. Total
cell proteins (10 μg/well) were added into a 96-well
microplate coated with total-/phospho-NF-κB p65
mouse monoclonal antibody and incubated for 2 h at
37°C. The plate was then washed with PBS containing
0.05% (w/v) Tween-20 (PBS-T) and 100 μl of total-
/phospho-NF-κB p65 rabbit monoclonal antibody was
added to the wells and incubated for 1 h at 37°C to de-
tect the captured total-/phospho-NF-κB p65 protein.
After washing with PBS-T, 100 μl of anti-rabbit IgG sec-
ondary antibody conjugated with horseradish peroxidase
(HRP) was added and incubated for 30 min at 37°C. To
develop the reaction, 100 μl of 3,3’,5,5’-tetramethylbenzi-
dine (TMB) substrate (Cell Signaling, MA, USA) was
added and incubated for 10 min at 37°C. Finally, 100 μl
of 0.18 M sulfuric acid was added to stop the reaction.
The optical density (OD) of the yellow-colored product
was determined with a microplate reader at 450 nm. All
assays were carried out in duplicate.Determination of NF-κB p65 nuclear translocation
The translocation of NF-κB p65 from the cytoplasm to
the nucleus was examined by immunofluorescence.
PBMCs were smeared on adhesive slides coated with 3-
aminopropyltriethoxysilane (Sigma-Aldrich, MO, USA)
and fixed with 3.7% formaldehyde in PBS (pH 7.4) for
20 min at room temperature. After fixation, the cells
were permeabilized with 0.5% Triton X-100 for 10 min.
After washing with PBS, the slides were blocked with 5%
BSA for 30 min at room temperature and incubated with
mouse anti-human NF-κB p65 (F-6) monoclonal anti-
body (1:200) (Santa Cruz Biotechnology, Santa Cruz,
CA) for 1 h at 37 °C. The slides were then incubated
with goat anti-mouse antibodies conjugated with Alexa-
488 (1:1000) (Invitrogen, Carlsbad, CA) for 45 min at
37°C. Finally, the slides were mounted with FluorSaveTM
reagent (Calbiochem, Nottingham, UK) and observed
under a fluorescence microscope (Olympus BX 41,
Tokyo, Japan) connected to a digital camera (Olympus
DP 20, Tokyo Japan) and a standard UV filter set. Nor-
mal PBMCs stimulated with 50 ng/ml of TNF for
30 min were used as a positive control and the omission
of primary antibody was used as a negative control. For
quantitative analysis, PBMCs (approximately 200–300
cells) were randomly examined by fluorescence micros-
copy under high power (x400) and cells stained positive
for nuclear NF-κB p65 were counted. To calculate the
percentage of cells with NF-κB nuclear translocation, the
number of positive nuclear stained cells was divided by
the total number of cell and the result was multiplied by
100.
Measurement of IL-10 and TNF in plasma of malaria
patients
The levels of IL-10 and TNF in plasma was determined
by the Human IL-10 and TNF ELISA Development Kit
(Peprotech, NJ, USA), a quantitative sandwich enzyme
immunoassay using a purified rabbit antibody against
IL-10 or by TNF pre-coated onto an ELISA plate (Nunc
Maxisorp F96, Roskilde, Denmark), and then incubated
overnight at room temperature. Human recombinant IL-
10 and TNF protein at serial concentrations and 2-fold
diluted plasma samples were incubated into the wells.
Assay standards and samples were added to duplicate
wells in the plate, which was incubated for 2 h at room
temperature. After washing, either a biotinylated purified
rabbit anti-human IL-10 or TNF antibody as the detec-
tion antibody was added to each well at a concentration
of 50 ng/ml and incubated for 2 h at room temperature.
Then, an avidin-horseradish peroxidase (HRP) conjugate
was added to the wells and incubated for 30 min at
room temperature. For color development, 2,2'-azino-bis
(3-ethylbenzothiazoline-6-sulfonic acid), or ABTS liquid
substrate (Sigma-Aldrich, MO, USA), was added and
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405 nm with wavelength correction set at 650 nm. The
sensitivity of the kit was within the range of 32–
2000 pg/ml for IL-10 and 16–2000 pg/ml for TNF.
Induction of NF-κB activation in healthy volunteer PBMCs
by malaria patient sera
To investigate whether the sera from malaria patients
could induce the expression of NF-κB p65 in PBMCs of
healthy volunteers, PBMCs (2 x 106 cells) were separ-
ately stimulated by 10% sera from healthy controls and
patients with P. vivax, uncomplicated P. falciparum, and
complicated P. falciparum malaria for 0, 30, and 60 min,
at 37°C, 5% CO2. TNF (50 ng/ml) was used as positive
control. After incubation, PBMCs were washed with PBS
and total proteins were isolated to detect the phospho-
NF-κB p65 using sandwich ELISA.
Statistical analysis
Data were expressed as mean ± standard error of the
mean (SEM). The normality of distribution was deter-
mined by the Kolmogorov-Smirnov test. Differences in
NF-κB p65 levels between groups were compared by un-
paired Student’s t-test. Student’s paired t-test was used to
assess differences in NF-κB p65 within groups. Differ-
ences in IL-10 and TNF cytokine levels between groups
were analysed by the Mann–Whitney test and the Wil-
coxon signed-rank test was used to compare the differ-
ence in cytokine levels within groups between day 0 and
day 7. In addition, the correlations within groups be-
tween levels of NF-κB p65 and pertinent clinical data in-
cluding age, days of fever, malaria parasite density, RBC,
WBC, haemoglobin, haematocrit, platelet, and cytokine
levels were calculated using Spearman’s rank correlation
(rs). Data was analysed by statistical analysis performed
using SPSS version 17.0 software (SPSS, IL, USA). The p
value< 0.05 was considered significantly different.
Results
Study subjects
The clinical and laboratory parameters of malaria patients
and healthy controls are shown in Table 1. On admission,
the mean parasite density was significantly higher in
patients with complicated P. falciparum malaria compared
to those with uncomplicated P. falciparum infection
(p=0.001). Patients diagnosed with P. vivax malaria were
administered chloroquine and primaquine, whereas
patients with P. falciparum malaria were treated with arte-
sunate and mefloquine. On day 7 post-treatment, no asex-
ual forms of malaria parasites were found in the
peripheral blood of all malaria patient groups. Complica-
tions in patients with complicated P. falciparum malaria
included pulmonary oedema (four of 11, 36.4%), cerebral
malaria (six of 11, 54.5%), acute renal failure (six of 11,54.5%), shock (three of 11, 27.3%), anaemia (six of 11,
54.5%), and acidosis (one of 11, 9.1%).
Activation of NF-κB p65 in the PBMCs of malaria patients
The total-NF-κB p65 levels detected in the PBMCs was
similar in all experimental groups (p> 0.05) on both day
0 and day 7 (Figure 1A). At admission, phospho-NF-κB
p65 levels were significantly elevated in the PBMCs of
patients with P. vivax (0.182 ± 0.04, p< 0.001) and un-
complicated P. falciparum malaria (0.250 ± 0.10, p
< 0.001), compared to the healthy controls
(0.104 ± 0.04). However, the phospho-NF-κB p65 levels
were significantly lower in the PBMCs of patients with
complicated P. falciparum malaria on admission com-
pared to day 7 post-treatment (0.086 ± 0.06, p= 0.01).
Among the patient groups, phospho-NF-κB p65 activity
was significantly higher in the PBMCs of patients with
uncomplicated P. falciparum malaria, compared to
patients with P. vivax (p= 0.01) or complicated P. falcip-
arum malaria (p= 0.001) (Figure 1B). On day 7 post-
treatment, phospho-NF-κB p65 activity was significantly
increased in the PBMCs of patients with complicated P.
falciparum malaria, compared to the healthy controls
(0.197 ± 0.03 vs 0.103 ± 0.01, p= 0.002) (Figure 1B).
Levels of phospho-NF-κB p65 remained significantly ele-
vated in PBMCs of the patients with P. vivax
(0.151 ± 0.01), whereas phospho-NF-κB p65 levels in
PBMCs from patients with uncomplicated P. falciparum
malaria showed an increasing trend, but this was not
statistically significant (p= 0.210) when compared to
healthy controls (0.103 ± 0.01). In addition, no difference
in the level of phospho-NF-κB p65 was found between
uncomplicated and complicated P. falciparum malaria
on day 7 (p> 0.05). No correlation was observed in any
group of patients between the level of phospho-NF-κB
p65 and other clinical parameters such as age, days of
fever, malaria parasite density, RBC, WBC, haemoglobin,
haematocrit, and platelet levels.
Nuclear translocation of NF-κB p65 in the PBMCs of
malaria patients
The work performed in the study demonstrated and
confirmed nuclear translocation of NF-κB in the PBMCs
from malaria patients by immunofluorescence assay
(Figure 2A). The percentages of NF-κB p65 nuclear
staining with immunofluorescence were consistent with
the findings of phospho-NF-κB p65 determined by
ELISA. At admission, the mean percentage of cells with
NF-κB p65 nuclear translocation was significantly
increased in patients with P. vivax and uncomplicated P.
falciparum malaria, compared to healthy controls
(55.0 ± 2.8% vs 44.8 ± 5.4% vs 13.2 ± 1.3%, p< 0.001, p
< 0.001, respectively) (Figure 2B). However, on day 7 the
mean percentage of cells with NF-κB p65 nuclear
Table 1 Clinical and laboratory parameters of malaria patients and healthy controls
P. vivax Uncomplicated P. falciparum Complicated P falciparum Healthy controls
Day 0 Day 7 Day 0 Day 7 Day 0 Day 7
Age (years) 25 (18–36) 31 (18–55) 35 (18–57) 26 (21–33)
Sex (Male/Female) 11/0 10/1 10/1 7/4
Duration of fever (days) 3 (1–5) 5 (2–9) 6 (3–9) None
Parasitaemia (/μl) 62,916 0 30,853 0 825,475# 0 None
WBC (103/μl) 6.3 7.4 6.5 5.6 8.5* 8.5* 6.6
RBC (106/μl) 4.9 5.0 4.1* 4.1 4.2* 3.6* 5.1
Haematocrit (%) 39.2* 39.3* 32.2* 32.0 34.0* 28.2* 44.6
Haemoglobin (g/dl) 13.2* 13.1 10.6* 10.4 11.6* 9.6* 14.3
Platelet (103/μl) 97* 303 106* 353 36* 226* 245
Data presented as mean. (n = 11 for each group).
#Significant difference (p< 0.05) vs uncomplicated P. falciparum malaria.









































































Figure 1 Activation of NF-κB p65 in the PBMCs of malaria patients determined by ELISA. (A) Total NF-κB level in the PBMCs of malaria
patients (n = 5 for each group). No difference in total-NF-κB p65 level was observed in PBMCs of all malaria patient groups, p> 0.05 compared
with healthy controls (Student t-test). (B) Phospho-NF-κB p65 levels in the PBMCs of malaria patients on day 0 and day 7 (n = 11 for each group).
Protein extract from PBMCs stimulated with 50 ng/ml of TNF for 30 min was used as a positive control. *Significance of p< 0.05 compared with
healthy controls (Student t-test), †Significance of p< 0.05 compared with the day of admission (Student t-test). Data are presented as a
mean± SEM.




























































Figure 2 Expression of NF-κB p65 in the PBMCs of malaria patients by immunofluorescence method. (A) Representative
immunofluorescence images of NF-κB p65 in the PBMCs of malaria patients on admission (a, b, c) and on day 7 post-treatment (d, e, f) compared
with healthy controls (HC) as evidenced by cytoplasmic NF-κB p65 staining (arrows) (g) positive control (PC) showing nuclear NF-κB p65 staining
(arrows) after stimulation with 50 ng/ml of TNF for 30 min (h) and negative control (NC) by omission of primary antibody (i). Bars = 10 μm. (B)
Quantitative analysis of the NF-κB p65 activation in PBMCs of malaria patients. *Significance of p< 0.05 compared with healthy controls (Student
t-test), †Significance of p< 0.05 compared with the day of admission (Student t-test). Data are presented as a mean± SEM.
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controls (Figure 2B).
IL-10 and TNF levels in the plasma of malaria patients
The expression levels of IL-10 and TNF in the plasma of
malaria patients are presented in Figure 3. Complicated
P. falciparum malaria had strikingly higher plasma IL-10
concentrations than P. vivax (p< 0.001) and uncomplicated
P. falciparum (p=0.002) patients during the acute illness(day 0). The mean plasma IL-10 on day 0 for P. vivax was
437.44 ± 104.60 pg/ml as compared with uncomplicated
P. falciparum (630.13 ± 183.78 pg/ml) and complicated
P. falciparum malaria patients (1,898.80 ± 666.50 pg/ml)
(Figure 3A). Nonetheless, levels of IL-10 in these malaria
groups were significantly higher than those of the healthy
controls (8.20 ± 5.96 pg/ml, all p< 0.001). On day 7,
the mean plasma IL-10 in the three malaria groups
declined significantly compared to their levels on day 0
Figure 3 Plasma concentrations of IL-10 and TNF in the
patients with P. vivax, uncomplicated P. falciparum and
complicated P. falciparum (n = 11 for each group) on day 0 and
day 7. (A) Plasma concentrations of IL-10 in three malaria patient
groups. *Significance of p< 0.05 compared with the mean value
determined on day 0, **Significance of p< 0.001 compared among
different malaria groups. (B) Plasma concentrations of TNF in three
malaria patient groups. *Significance of p< 0.05 compared among
different groups. Data are presented as mean± SEM.
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464.30 ± 169.00 pg/ml for uncomplicated P. falciparum
(p = 0.041), and 331.26 ± 61.41 pg/ml for complicated
P. falciparum malaria patients (p = 0.010)). The mean
plasma levels of IL-10 in P. vivax patients were not sig-
nificantly different from those observed in uncompli-
cated P. falciparum patients on both day 0 (p> 0.05)
and day 7 (p> 0.05), and on day 7 of patients with
complicated P. falciparum malaria (p> 0.05) (Fig-
ure 3A). Eventually, on day 7, circulating IL-10 levels
were found to decline and returned to the same levels
as for P. vivax and uncomplicated P. falciparum.At admission, plasma TNF was markedly elevated in
patients with P. vivax (231.08 ± 47.89 pg/ml), uncompli-
cated P. falciparum (331.70 ± 77.55 pg/ml), and compli-
cated P. falciparum (479.64 ± 133.53 pg/ml), compared
with the healthy controls (10.35 ± 10.02 pg/ml, all
p< 0.001). The mean TNF concentration of patients
with complicated P. falciparum was significantly higher
than patients with P. vivax malaria (p< 0.05) (Figure 3B).
TNF concentrations were monitored at day 7 and the
levels were 211.19 ± 51.73 pg/ml, 237.65 ± 73.39 pg/ml
and 263.95 ± 70.25 pg/ml for P. vivax, uncomplicated P.
falciparum and complicated P. falciparum malaria
patients, respectively. TNF concentrations did not differ
within each group of malaria patients at admission and
day 7 post-treatment (all p> 0.05) (Figure 3B). In
addition, there was no correlation between the plasma
levels of IL-10 and TNF in any malaria groups.
Correlations between NF-κB p65 in PBMCs and plasma
IL-10
In complicated P. falciparum malaria, a significant nega-
tive correlation between phospho-NF-κB p65 in PBMCs
and plasma level of IL-10 (rs=−0.630, p= 0.038) was
established during acute illness. No correlation was
observed between phospho-NF-κB p65 in PBMCs and
plasma TNF in any of the malaria groups.
Effect of malaria serum on NF-κB p65 in the PBMCs of
healthy controls
The level of phospho-NF-κB p65 in the PBMCs
increased significantly in response to sera from all mal-
aria patient groups (P. vivax, uncomplicated P. falcip-
arum, and complicated P. falciparum malaria) at 30 min
after stimulation (Figure 4) with the highest stimulation
by sera from uncomplicated P. falciparum malaria. In
addition, the levels of phospho-NF-κB p65 activation
induced by sera from patients with uncomplicated P. fal-
ciparum malaria were significantly higher than those
induced by sera from patients with complicated P. fal-
ciparum malaria (p= 0.044). However, this effect seems
to be transient. In the present study, the level of
phospho-NF-κB p65 induced by sera from patients
showed a tendency to return to the pre-stimulation state
after 60 min (Figure 4).
Discussion
This is the first report showing NF-κB expression in the
PBMCs of malaria patients and its correlation with IL-10
and TNF by using sandwich ELISA. The use of ELISA has
become a powerful method for measuring protein phos-
phorylation. ELISA is more quantitative than Western blot-
ting and possesses high specificity and sensitivity due to the
use of two antibodies specific for the target protein
employed together in the sandwich. NF-κB p65 activation
Figure 4 Malaria sera-induced NF-κB p65 activation in the PBMCs of healthy controls (n = 5). The protein extracts (10 μg/well) of the
PBMCs from healthy controls after stimulation with serum from malaria patients were analysed for phospho-NF-κB level using ELISA. The results
demonstrated significantly increased levels of phospho-NF-κB p65 in the PBMCs in response to malaria-patient sera after 30 min of stimulation
with 10% serum from malaria patients with P. vivax, uncomplicated P. falciparum, and complicated P. falciparum malaria. TNF treatment was used
as positive control and PBMCs treated with media was used as untreated or negative control. *Significance of p< 0.05 compared to normal
serum treatments (Student t-test). ΔSignificance of p< 0.05 compared between groups. Data are presented as mean± SEM.
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P. falciparum patients, on both day 0 and day 7, whereas in
complicated P. falciparum patients, elevated NF-κB p65 ac-
tivity was observed only on day 7 post-treatment. NF-κB
activation may be triggered by various ligands or proteins
of malaria parasites that induce up-regulation of the NF-κB
signaling pathway, leading to nuclear translocation of NF-
κB and regulation of gene expression. It is possible that the
increased NF-κB p65 levels in the PBMCs with malaria in-
fection are involved in the enhancement of inflammatory
cytokines. Consistent with the increased level of phospho-
NF-κB p65 in the PBMCs, the immunofluorescence assay
confirmed NF-κB p65 immunostaining in PBMC nuclei, in-
dicating the active NF-κB protein state in malaria infection.
Data from the literature of experimental in vitro malaria
studies show that the mechanisms induced or involved in
the activation of NF-κB p65 include haemozoin (HZ)-
induced enhancement of inflammatory cytokines [11,16-
18], activation of matrix metalloproteinase-9 (MMP-9) in
human monocytes fed with trophozoites and HZ [19], and
P. falciparum glycosylphosphatidylinositol (GPI) stimulat-
ing monocytes and macrophages, leading to the activation
of NF-κB downstream signaling pathways induced expres-
sion of pro-inflammatory mediators, such as TNF, IL-6, IL-
12, and nitric oxide (NO) [12,13]. Recent investigations
studied the innate immune response in malaria infection,
showing that Toll-like receptor 1 (TLR1), TLR2, and TLR4
were induced in PBMCs from both experimentally [14,20]
and naturally acquired malaria infections [14]. These find-
ings suggest that the activation of TLRs by GPI [21] andHZ [22] transmit signals in an intracellular pathway leads
to the activation of transcription factor NF-κB, which in
turn propagates a signal to the nucleus to regulate the ex-
pression of pro-inflammatory cytokines. Consequently,
these actions could cause increased levels of phospho-NF-
κB p65 and nuclear translocation of NF-κB p65 in the
PBMCs of malaria patients.
NF-κB p65 activity was decreased in PBMCs from
patients with complicated P. falciparum at admission,
consistent with the reduced mean percentage of NF-κB
p65 nuclear translocation evidenced by the immuno-
fluorescence study. These findings agree with previous
reports which demonstrated that PBMCs from patients
with sepsis and major trauma reduced the active form of
NF-κB p65 on the day of admission [23,24]. The silen-
cing of NF-κB p65 gene expression reported in severe
systemic inflammation may also explain the important
signaling event in complicated P. falciparum wherein
NF-κB p65 could be repressed by cytokines [25]. Studies
have shown that immunosuppressives such as TGF-β
[26,27] and IL-10 (also known as anti-inflammatory
cytokine) [28] reportedly alter NF-κB expression and
translocation, and contribute to cell desensitization [26-
28]. Normally, IL-10 is produced by macrophages as well
as T and B lymphocytes, and has been shown to play a
significant role in immunoregulation, involving negative
feedback on the production of pro-inflammatory cyto-
kine [29]. It has been reported that increasing plasma
IL-10 was detected in cerebral and severe malaria
patients at admission, in contrast to the patients with
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10 levels have been detected in serum of Thai patients
with acute P. falciparum malaria prior to treatment and
the levels were found to return to normal after malaria
treatment [31]. To investigate whether the decrease in
nuclear translocation of NF-κB found in complicated P.
falciparum malaria patients is linked to plasma IL-10
levels, IL-10 levels were determined in the malaria
groups. In this study, the plasma level of IL-10 was sig-
nificantly elevated in complicated P. falciparum malaria
infection and had a negative correlation with phospho-
NF-κB p65 expression at admission. When the IL-10
levels were high, the phospho-NF-κB p65 levels were
low. This correlation was not found in P. vivax or un-
complicated P. falciparum infections. At admission, the
plasma levels of IL-10 in patients with complicated P.
falciparum malaria were 4.3 times and 3 times higher
than in patients with P. vivax and uncomplicated P. fal-
ciparum, respectively. This observation suggests that
decreased levels of NF-κB p65 in the PBMCs of compli-
cated P. falciparum patients during acute infection could
be due to a negative feedback loop mechanism, or the
consequence of high levels of IL-10, an important anti-
inflammatory cytokine associated with severe disease. It
has been shown that IL-10 inhibits NF-κB activation
rapidly and in a dose-dependent manner [28]. At day 7
post-treatment, the plasma levels of IL-10 in compli-
cated P. falciparum malaria declined 5.7 times from the
level on day 0, to the same levels as the P. vivax and un-
complicated P. falciparum malaria groups. This trend is
similar to results in a previous report [30]. The lower
level of IL-10 could explain the elevated level of acti-
vated NF-κB in the PBMCs from complicated P. falcip-
arum malaria at day 7 post-treatment.
Furthermore, the study investigated whether malaria
patient serum could induce NF-κB p65 activation in un-
stimulated PBMCs. Significantly, transiently increased
levels of phospho-NF-κB p65 were found in the healthy
PBMCs 30 min after stimulation with malaria serum,
consistent with previous studies on endothelial cells
[32], monocytes [33], and human cardiac myocytes [34].
However, the transient increased of phospho-NF-κB p65
in malaria sera-induced healthy PBMCS did not concur
with the decline of NF-κB p65 at admission in compli-
cated P. falciparum malaria. The PBMCs from healthy
controls are naïve and activation is short-lived. The ef-
fect might not be long enough to initiate a complex re-
sponse to malaria serum. In contrary, the PBMCs
collected from complicated P. falciparum malaria
patients was sensitized by prolonged infection and re-
sponse mechanisms induced by other cell signaling pro-
cesses. The present study elucidates that sera from
malaria patients can induce NF-κB p65 activation in
naïve PBMCs. It would be helpful to further analyse theexpression of NF-κB in PBMCs from malaria patients
after stimulation with malaria sera to determine the
event of “desensitization” in malaria. Further work to in-
vestigate whether pre-incubation of the malaria sera with
an anti-IL-10 neutralizing monoclonal antibody would
suppress NF-κB activation in PBMCs from complicated
P. falciparum patients will be of interest.
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